TABLE 3

Drug binding properties at the EGFP(Δ17)hM1 receptor and its mutants as assessed from equilibrium and kinetic [3H]NMS binding

Equilibrium affinity constants (−log M) are from [3H]NMS saturation studies (pKd values) and from competition-type experiments analyzed according to competitive (pKi values) or allosteric ternary complex (pKX values; cooperativity factor pα) binding models. pEC50,diss (−log M) and Emax,diss (percentage given in parentheses) parameters refer to midpoint and maximal extent of retardation curves for [3H-NMS] dissociation (Data Analyses). Given are the means ± S.E. for 3–10 separate experiments performed as detailed in Materials and Methods.

EGFP-wt hM1EGFP-W405AEGFP-W405FEGFP-W400AEGFP-W400F
pKd,i,xpEC50,diss (Emax, %)pKd,i,x pαpEC50,diss (Emax, %)pKd,i,x pαpEC50,diss (Emax, %)pKd,i,x pαpEC50,diss (Emax, %)pKd,i,x pαpEC50,diss (Emax, %)
[3H]NMS Bmaxa10.02 ± 0.03 445 ± 35a10.27 ± 0.04 400 ± 75a10.28 ± 0.03 910 ± 125a10.04 ± 0.01195 ± 15a10.04 ± 0.04 395 ± 45a
Atropine9.19 ± 0.039.30 ± 0.089.57 ± 0.019.35 ± 0039.03 ± 0.06
Pirenzepine8.03 ± 0.087.73 ± 0.018.24 ± 0.047.65 ± 0.107.89 ± 0.23
Carbachol4.89 ± 0.145.58 ± 0.195.18 ± 0.014.68 ± 0.124.53 ± 0.12
Gallamine5.04 ± 0.063.94 ± 0.07 (100)4.88 ± 0.064.00 ± 0.04 (100)4.74 ± 0.023.82 ± 0.05 (100)3.96 ± 0.032.35 ± 0.03 (100)b4.10 ± 0.073.25 ± 0.07 (80 ± 5)
-1.12 ± 0.02c-0.89 ± 0.02c-0.78 ± 0.07c-1.21 ± 0.04c-0.92 ± 0.07c
Brucine4.59 ± 0.02d4.49 ± 0.02 (100)N.A.e5.02 ± 0.03 (100)N.A.e4.79 ± 0.03 (100)N.A.e3.31 ± 0.06 (77 ± 4)N.A.e3.68 ± 0.05 (85 ± 3)
-0.10 ± 0.02c
  • N.A., not applicable; wt, wild type.

  • a Maximal densities in [3H-NMS] binding sites (Bmax, fmol/106 cells) are from saturation experiments.

  • b EC50,diss is from curve fitting to eq. 8 with Emax,diss constrained to 100%.

  • c Cooperativity factor (negative logarithm).

  • d EC50,diss was used for curve fitting according to eq. 5 because of nearly neutral cooperativity (Data Analyses).

  • e Not applicable. Over a 1–300 µM concentration range, brucine did not significantly modify equilibrium [3H]NMS binding at the mutants.